It has been a hectic year for Crispr Therapeutics AG, which is ending with a flourish following the announcement that Leverkusen, Germany-based Bayer AG is investing a total of $335 million in order to establish a long-term alliance that will leverage promising CRISPR-Cas9 gene-editing technology.